Home / Transcripts / electroCore, Inc. (ECOR) · May 6, 2026

electroCore, Inc. (ECOR) Earnings Call Transcript

May 6, 2026

NASDAQ US Health Care Health Care Equipment and Supplies earnings 51 min

Earnings Call Speaker Segments

Joseph Errico executive
#1

Thanks, Amanda. Hello, everyone, and I appreciate you being on ElectroCore's call for Q1 2026 results. We've announced a change in leadership, and this marks our initial earnings discussion since then, so I'd like to briefly express how heartened I feel about what we've accomplished in carrying out that change and the energy we keep observing throughout the company. After taking on the Interim President position, Josh has delivered consistent, well-disciplined guidance and stayed dedicated to strong financial practices. It's been clear that our operational goals line up with our financial approach, and the whole organization has met this with concentration and a sense of urgency. Our strategy remains the same. We haven't decelerated in how we execute. If there's any shift, it's that everyone's attention has become even more focused. Meanwhile, Michael Fox came aboard as Chief Operating Officer on April 13, and he brings over 35 years of experience leading commercial efforts in intricate health care sectors, which includes considerable involvement with federal systems and the U.S. Department of Veterans Affairs. In only 3 weeks, the breadth of his background has already offered useful perspectives that sharpen how we carry things out, especially as we keep broadening our footprint in complicated government distribution networks. He'll be introducing himself in a bit. The key point is that this change hasn't caused us to lose speed. Instead, it has strengthened what we're built on. We stay fully dedicated to our approach: generating growth among our covered entities, pushing forward our clinical and scientific authority in noninvasive vagus nerve stimulation, and extending our footprint in the consumer wellness sector—all while exercising discipline, controlling expenses, improving margins, and safeguarding our route to profitability. When it comes to clinical efforts, we keep putting resources into the body of evidence supporting our portfolio. That evidence continues to serve as a crucial point of distinction when we deal with providers, payers, and partners both around the world and here at home, and it sets us up to move into additional indications as time goes on; in the VA, where we've established a trustworthy commercial footprint over numerous years, we think there's a significant opportunity ahead. Our commercial leaders are using Mike's background to find fresh approaches that are more focused and yield better results, especially in a system where plenty of untapped potential remains. On the consumer front, we're creating a direct-to-consumer channel that can scale, with brand recognition on the rise, better unit economics, and an expanding web of influencer and affiliate collaborators who connect with people looking for wellness options that are non-pharmacologic and supported by science. The initial momentum we're witnessing bolsters our conviction about the wider uses of our technology and how it applies to daily wellness. What instills the most confidence in me isn't merely the initiative itself, but the manner in which it's being carried out—with discipline, unity, and a shared clarity of mission throughout the company. We're laying a solid groundwork, and we're doing it in a manner that sets the company up for lasting growth over the long haul. As we keep looking for a CEO to fill the role on a permanent basis, I have every confidence that the group currently in place — Josh, Mike, and the wider leadership team — is the correct one to deliver on what we have prioritized and to move our strategy ahead. I am eager to share news of how we keep advancing in the coming quarters. So now let me bring in the person who has just become our Chief Operating Officer, Mike Fox. Mike?

Executive executive
#2

Thanks, Tom. Good afternoon, everybody. There was one reason I came to ElectroCore. I identified a platform technology rooted in science, backed by clinical outcome data that's published and proven, which supports a solid commercial base and plenty of space to grow — especially in the federal channels, where I've worked for the bulk of my career. Now that I'm 3 weeks in, that belief has only gotten firmer, thanks to deeper exposure to the current and upcoming data sets being compiled. I've also gotten to meet a large number of highly talented people across this company who are committed to the mission and to the patients we serve. So instead of going through my résumé, I'll tell you what I've been concentrating on and where the opportunity lies. A top priority is the VA and Department of Defense markets. When it comes to reaching the addressable VA headache market, we've barely made a dent. Patients are being treated with our products at VA medical centers nationwide, yes, but the utilization level we're hitting doesn't match what our veterans need, nor what the dedicated providers caring for these military heroes need. Most of the new patients identified and prescribed our products in Q1 aren't distributed around the country the way we'd expect or the way it's needed. That tells me 2 things. First, we've built genuine distribution; second, we're far from saturation. My focus is shifting from breadth across facilities to depth within facilities — more prescribers at each site, more patients for each prescriber, and a customer experience that's more consistent system-wide. Priority number two is the wider federal channel. The VA is our biggest entry point, though it isn't the sole one. Across every service branch, the Department of Defense represents an underdeveloped opportunity for our prescription products as well as for TAC-STIM. With the heightened tempo of U.S. military operations abroad, demand for noninvasive, drug-free performance-supporting solutions has only grown more intense. I've spent the last 3.5 decades cultivating relationships in these channels, and I plan to put them to work for this company. Priority number three is operating discipline. Josh and the team have built a high-margin business — 87% gross margin in Q1 — and operating leverage is beginning to appear in the numbers. My job is to ensure that as we scale, incremental revenue becomes incremental bottom line, not incremental costs. We plan to grow this business efficiently while establishing ElectroCore as a partner of choice, so we can ensure market stability in the years ahead. I'm 3 weeks in, but rest assured my experience in developing company growth and success comes from decades of learning and proven execution strategies. I'm genuinely excited about the opportunity in front of me here at electroCore. There will be a great deal more for me to share over the coming quarters, but I'm convinced that what lies ahead of us is real, and I'm truly grateful to be part of it. With that, I'll hand the call back to Josh to walk through the quarter. Josh?

Josh Lev executive
#3

Thanks, Mike. Before diving into specifics, I want to frame what this quarter means for electroCore: we posted record revenue of $9.6 million, which is 43% higher than the same period last year. Gross margin came in at 87%. On a GAAP basis, net loss was $5.3 million, while our adjusted EBITDA loss narrowed by 24%, landing at $2.3 million. When you put those pieces together — faster top-line growth, better margins, and a smaller adjusted EBITDA loss, all within one quarter — that shows operating leverage at work, and it's the strongest evidence so far that our strategy is being executed. We're holding steady on our 2026 full-year revenue outlook, which calls for roughly 30% growth. As I'll get into shortly, the upcoming catalysts for 2026 are what give us confidence in that number. Now, the specifics. Our biggest customer is still the VA hospital system, and growth there keeps speeding up. Prescription device revenue climbed 48% versus a year ago, reaching $7.9 million. Inside that figure, prescription gammaCore was up 26%, and Quell sales had their first quarter above $1 million. Since picking up the Quell assets from NeuroMetrix back in May 2025, Quell fibromyalgia has brought in $2.5 million cumulatively, and we've barely begun rolling that product out across the VA system. As of March 31, about 15,000 VA patients had received the gammaCore device, which we figure is around 2.5% penetration into the addressable VA headache market. That patient base keeps growing. A 2024 study in JAMA Network Open looking at nearly 500,000 U.S. veterans found that 8.2% of men and 30.1% of women among veterans have a migraine history — about 3x what's seen in civilians — and that roughly half of veterans dealing with migraine also qualify for PTSD. The U.S. Department of Defense has counted over 485,000 traumatic brain injury diagnoses among service members since 2000. When you factor in the Veterans Health Administration's initiative to make non-opioid options the initial course of treatment for chronic pain, there's a substantial opportunity ahead for prescription gammaCore to gain traction across the VA — and we've only just begun. Turning to our consumer wellness segment: quarterly revenue reached $1.6 million, which is 44% higher than the same period a year ago, with Truvaga contributing $1.5 million, marking a 38% rise over Q1 of last year. This quarter, we deliberately restrained top-line expansion in order to focus on efficiency, and the results of that are now apparent in our unit economics. Our return on advertising spend, or ROAS, was roughly 2.37 for the period — an improvement of 14% compared with the prior quarter. Put simply, each dollar spent on Truvaga-related media brought back close to $2.37 in revenue. That gain came from a deliberate pivot toward affiliate and influencer partnerships, which connect us with consumers who already have an interest in wellness and specifically in vagus nerve stimulation. Return rates stayed in the 12% to 15% band, in line with earlier periods. We see the broader environment for our consumer wellness offering as significant. According to the Centers for Disease Control, about 24.3% of U.S. adults dealt with chronic pain in 2023, an increase from 20.4% in 2019. According to independent industry research, the worldwide noninvasive vagus nerve stimulation market is expected to grow at a low double-digit CAGR through 2030, driven by aging populations, a regulatory and clinical shift toward non-opioid pain management, and greater consumer awareness of the vagus nerve. We feel Truvaga is positioned well to take a meaningful portion of that expansion; turning to TAC-STIM, our human performance offering. Although TAC-STIM revenue by quarter has been uneven historically, demand fundamentals for cognitive performance and fatigue reduction across active duty military and federal channels remain strong and are strengthening further. With the increased pace of U.S. When it comes to military missions abroad—particularly those using remotely piloted aircraft, drone defense, and similar long-endurance profiles—there's a growing need for noninvasive, drug-free solutions that help war fighters stay alert, focused, and resilient. TAC-STIM continues to undergo study and evaluation through the U.S. Air Force Special Operations Command, the U.S. Army Special Operations Command, and the Air Force Research Laboratory. Earlier, AFRL selected it for the real-time assessing and augmenting cognitive performance in extreme environments program—a program designed in part to aid multi-day transoceanic operations as well as long-duration remotely piloted aircraft missions. With Mike now at the helm of our commercial operation, we anticipate a significant opportunity in 2026 and beyond to deepen our engagement and to establish TAC-STIM as a steadier contributor to revenue. Turning to the financials: net sales came in at $9.6 million, which was 43% growth compared to the prior year, powered by gammaCore and Quell within the VA along with ongoing expansion in Truvaga. Gross profit reached $8.4 million, and gross margin widened to 87%, which is a 200 basis point gain year-over-year. Research and development expense totaled $740,000, a slight increase from the prior year, mainly reflecting work on the ACACIA PTSD study. Selling, general, and administrative expenses amounted to $12.9 million. Within that figure, you'll find roughly $1.9 million tied to one-time leadership transition costs, plus $300,000 in legal fees stemming from the IP litigation that's still ongoing. Once you strip those out, the growth compared with last year came mostly from about $1.6 million in variable expense that accompanied our $2.9 million lift in revenue — a clear demonstration of how our cost structure expands alongside the top line. The $276,000 in other expense reflects interest on the convertible term debt financing we arranged with Avenue Venture Opportunities Fund. On a GAAP basis, our net loss for the first quarter reached $5.3 million, versus $3.9 million during the same period a year earlier. What mainly pushed that figure higher was the $1.9 million in nonrecurring leadership transition costs. On a per-share basis, our net loss came to $0.59, whereas the comparable quarter a year ago showed $0.47 per share. If you back out the costs tied to the leadership transition, the net loss per share would have been $0.37. I'd also like to highlight that our adjusted EBITDA loss improved by 24%, something I see as a meaningful sign of the operating leverage we're generating. Adjusted EBITDA loss for the first quarter totaled $2.3 million, compared with $3.1 million in last year's same period. That improvement occurred in a quarter when we absorbed $1.9 million of nonrecurring leadership transition expenses. Once you remove those, the operating leverage inherent in this business stands out even more clearly. Our top line grew 43%, and our adjusted EBITDA loss got 24% smaller. Bringing that shortfall down further as we keep expanding is the path to turning a profit. A reconciliation showing how GAAP net loss maps to non-GAAP adjusted EBITDA net loss appears in the financial tables of the press release we issued today. Turning to the balance sheet: as of March 31, 2026, we held about $8.8 million in cash, cash equivalents, and marketable securities, compared with $11.6 million on December 31, 2025. One thing worth noting regarding cash. Usually, the first three months of the year represent the period when our cash usage peaks; in 2026, certain working capital line items — primarily inventory scheduling and capital upgrades at the Rockaway site — may shift a portion of that usage into Q2; we're managing the balance sheet prudently and keeping our attention on the operational efficiencies that support our route to profitability, while simultaneously evaluating the capital sources at our disposal, including our current shelf registration statement and at-the-market facility. Prior to opening the floor to questions, I want to spend a moment discussing the catalysts ahead of us for 2026, given that the distance still to travel from this point is considerable. To begin, R&D and nVNS as a platform technology.

Josh Lev executive
#4

Our focus remains on building out a suite of products capable of moving through the sales channels we already have in place — and that takes shape as indications, products, and features. Evidence keeps piling up that supports nVNS and its therapeutic promise. A fresh piece in Frontiers in Neuroscience, titled 'Adjunctive non-invasive vagus nerve stimulation for chronic mild traumatic brain injury with comorbid post-traumatic stress disorder, a post-hoc analysis, brought forward findings about possible advantages of adjunctive noninvasive vagus nerve stimulation for patients dealing with mild traumatic brain injury and PTSD. On top of that, roughly 20 participants are now signed up for a clinical study run by Acacia Clinics alongside the Vagus Nerve Society, aimed at assessing how safe and effective electroCore's gammaCore nVNS device is as an adjunctive treatment for symptoms tied to PTSD. For us, PTSD holds a breakthrough device designation; as the data continues to mature, we anticipate it will grow into an ever more significant piece of the platform narrative. Development is ongoing on our next-generation Truvaga and Quell mobile platform; we're building a mobile application meant to pair with our consumer products, offering more personalized features and user experiences and, if executed well, unlocking recurring revenue, stronger engagement, and richer real-world data. Number two, we stay focused on unlocking further commercial channels for what we sell. Alongside ongoing VA penetration, Mike's mandate covers growing our presence in commercial and federal channels. That spans things like Kaiser, federal workers' compensation programs, TRICARE, and wider adoption among active duty military and the Department of Defense; since TAC-STIM is already engaged across Air Force Special Operations Command, Army Special Operations Command, and the Air Force Research Laboratory, we see substantial room for more federal contract activity. Quell keeps picking up adoption via our existing sales channel, mainly inside the VA. Revenue from the Quell product line topped $1 million in a quarter for the very first time in Q1 2026, lifting cumulative Quell revenue to about $2.7 million since the acquisition from NeuroMetrix in May 2025, which includes $2.5 million of Quell fibromyalgia sales in the VA. We have a modest group of legacy Quell over-the-counter users and anticipate relaunching the over-the-counter Quell relief for lower extremity pain later this year. Back in January 2026, we brought Truvaga to the United Kingdom. And as that business grows, we expect to look at additional markets. Number three, possibly the biggest catalyst of them all, is our route to profitability. The math is simple: mid-80s gross margin, top line accelerating, cost base growing more disciplined. We aren't ready yet to name a specific quarter for breakeven, but the trajectory is clear, and Q1 offers the strongest proof yet that we are on it. All together, these catalysts support our reaffirmed full-year 2026 revenue guidance of approximately 30% growth, which works out to roughly $9 million to $10 million of incremental revenue against our $32 million in 2025. We anticipate that most of that expansion will be driven by ongoing growth in VA prescriptions, which by itself produced 48% year-over-year prescription device revenue in Q1. The next significant contributor is Truvaga, expanding in the high 30% range while becoming more efficient. Newer contributions come from Quell Relief and our international launch, which we hope to scale during the back half of the year. TAC-STIM has historically been uneven, but it offers potential upside as Mike strengthens our federal engagement. Meanwhile, our next-generation mobile platform will contribute in 2027 and creates opportunities for recurring revenue over time. To put it briefly: 3 catalysts, an obvious 30% growth bridge starting from 2026, and a longer runway into 2027 and beyond. With that, I'd like to open the call for questions. Operator?

Destiny Buch analyst
#5

Destiny here, filling in for Jeff. I wanted to ask about the VA channel, and this will be a question with a few parts. But what I'm curious about is: as you shift from breadth toward depth in that channel, does your sales force structure change when it comes to W-2 versus 1099? And then, how do you weigh opening new sites against treating more patients, or rather, more patients treated?

Josh Lev executive
#6

Hey Destiny, thanks so much for asking. I really appreciate it, and I appreciate that you're on the call today. The person best suited to address that would be Mike. Mike, why don't you jump in and tell everyone what your strategy is?

Executive executive
#7

Yeah. Thank you, Josh. In my view, that's a very solid question, since based on what I've seen, this isn't a matter of choosing one option over another — growing our breadth is absolutely something we want. VA utilization exists throughout the country, yet the depth across different specialties and patient segment groups hasn't reached the level it should. The 1099 model appeals to me. The W-2 model appeals to me as well. Throughout my career, provided we have high-caliber performers who share a strong commitment to serving our veterans, we can create a truly robust opportunity built on that foundation. So rather than seeing this as some major shift, I view it more as an internal alignment priority and a chance for us to make sure we're establishing the right expectations and truly keeping people answerable for surpassing those expectations, for our gammaCore line as well as the Q. Destiny, does that address what you asked?

Destiny Buch analyst
#8

That does. Beyond that, I'm just wondering what goal you have in mind for how many clinics there will be once 2026 wraps up — maybe some range that starts from that figure of 200?

Executive executive
#9

At this moment, it hinges on what we mean when we talk about clinics. I'm quite fond of. Clinic centers. Right, the VA medical centers hinge on whichever figure you decide to work with. My long-held view is that unless we're reaching a minimum of 75% of the facilities nationwide to assist the vets, we aren't fulfilling our duties. An exact figure eludes me, yet we must become genuinely proactive and achieve steady use of our products, serving veterans at no fewer than 75% of those accounts every month.

Destiny Buch analyst
#10

So once you move into those other DoD channels, what does that process look like next to the VA centers? Is the timing comparable?

Executive executive
#11

The story is likely to be entirely different, since both of them sit under FSS, as you're aware, yet the Department of Defense accounts — the military health centers, for instance — also carry the TRICARE component. That means you have distinct segments; still, when it comes to how long things take, getting set up through the VA tends to be a lengthy affair because of FSS and coordinating with our customers, such as global government services on certain items. Over on the Department of Defense side, my expectation is that at some point in Q3 or Q4, once our plan is in place, we'll begin to see revenue come in.

Destiny Buch analyst
#12

Moving on to wellness and Truvaga, your ROAs this quarter are really strong, and I think that's fantastic. I'm curious whether any adjustments to the marketing channels contributed to that improved ROAS.

Executive executive
#13

Yes. That's a great question, I'd say. It isn't really a shift in the marketing channels; it's more about where our resources are being deployed and invested. We put a more concerted effort into affiliate programs and influencers. You might have noticed that Miranda Kerr posted about us earlier. That's a co-marketing opportunity that we have; with those opportunities, what we could do is utilize and leverage other people's marketing budgets, so that they're actually the ones putting the marketing messaging out there. And really, what we're doing is using that halo effect to help lift our efficiency; so it isn't really a change per se. I wouldn't say we cut out any of the other channels or media that we've done before. We're just reallocating the resources and looking at it slightly differently.

Destiny Buch analyst
#14

And when it comes to repeat buying patterns or similar things, have you seen any changes versus a year ago?

Executive executive
#15

Not at this point, though we haven't provided any official guidance on that matter. For now, I'd say not yet. It all appears to be normal operations.

Fozia Ahmed analyst
#16

To start, Mike, I appreciate you being on this call and stepping into the role; we're eager to work with you. My question concerns the FRONTIER study involving PTSD patients, which was quite persuasive. Could you remind us how that study lines up with the ACACIA trial that's currently underway? Is the design identical, and are the endpoints meant to measure the same things that appeared in FRONTIER, or is it something else?

Executive executive
#17

It's a bit different. The purpose of each is to enroll PTSD patients and to measure what happens when noninvasive vagus nerve stimulation is used in that population. The protocols themselves differ somewhat. Those can be reviewed on the IRBs if you wish. Essentially, the concept is aggregating various data points where PTSD is being examined within a patient population, though those populations might not be exactly alike.

Fozia Ahmed analyst
#18

Then I've got a second question for you. A breakthrough designation is linked to PTSD. At this moment, are there any active talks happening with the FDA?

Executive executive
#19

During earlier quarters, we provided details and discussed the manner in which we had exchanged views with the FDA regarding the optimal route for broadening that breakthrough designation into something that would become a formal PTSD label. Much of the effort we're engaged in right now, mainly involving the ACACIA study and the item you mentioned just a moment ago, is essentially pulling together additional data points and information that we can present to the FDA so there could be a complete rollout of a PTSD indication and a complete label. And we're carrying that out in tandem with them, in the sense that they have pinpointed or spelled out for us the things they want; and drawing on those details, we intend to take that and gather the data set together to hand over to them so we can in the end seek the full form PTSD.

Swayampakula Ramakanth analyst
#20

Afternoon, Joshua, and glad to have you with us, Michael Fox. I hope the audio is coming through for you both. There are a couple or three things I want to ask. So Josh, to begin with, I appreciate you restating that 30% growth figure for 2026. However, Q1 delivered a 43% gain; so what's holding you back from being more cautious than necessary? Is there something that makes you — I won't say worried, but makes you feel like I should hold off for at least one more quarter before revising that guidance?

Josh Lev executive
#21

Excellent question, RK, and quite perceptive. No is the answer. Above all else, we've got internal projections, as you're aware, and the guidance we gave to the Street really rests on what we think organic growth might look like according to, I'd call it, a stale model, so to speak. And by stale, I mean that Mike, bringing all the experience he has from joining this organization, has applied strategy and tactics that previously helped grow his other businesses 3x to 4x when it comes to top-line revenue. Mike arrived here only on April 13th. So it isn't really necessarily "fair" or easy to anticipate any further kind of direction or tactics regarding how that growth can be expanded or accelerated, what the timing for that growth will be and the resources needed, which is why we keep returning to — we'll give more detailed guidance once it's available and more appropriate. There simply hasn't been sufficient time for Mike to fully get his feet wet so he can map things out and say, Okay, I believe we can grow by x, but it's going to require this amount of time.

Swayampakula Ramakanth analyst
#22

Michael Fox, like I mentioned earlier, glad to have you with us. Here's something I'd like to ask you quickly. While you were carrying out your due diligence and preparing to join, gammaCore has already been sold into VA facilities for a good amount of time. Roughly 200 sites exist where the product isn't just being purchased but kept in inventory. Drawing on your background and your prior work, which opportunities in the VA market would be simplest to leverage toward expanding into more sites? Also, beyond the VA, could you identify one or two other federal locations where you believe selling would be relatively straightforward?

Executive executive
#23

RK, that's a great question. Based on what I've observed through my VA experience, the most effective approach for making inroads there is partnering alongside them. Standardization is huge at the VA. They generate numerous demands around algorithms and treatment protocols, plus medical necessity. My observation is that many companies accomplish impressive things account by account, yet they fail to engage leadership at either the business or national level to properly establish where their product belongs and secure top-down backing. My sense is this company has excelled at building bottom-up support. What I'm able to contribute is to keep leveraging that information, that data, the outcomes reported by patients, and the details our providers in the VA have collected, in order to create additional chances for standardizing treatment and establishing a very strong position for gammaCore across the federal space. Regarding your question's second part, beyond the VA, I'm aware of a substantial federal workers' comp possibility given how many headaches and migraines occur in that area. When it comes to the Department of Defense, saying Department of Defense should bring to mind facilities such as Walter Reed, SAMMC, Portsmouth, Naval, and Balboa. So many medical facilities exist that serve patients after deployment, people returning with assorted conditions we can certainly help them with. So my assessment of where we'll be able to begin is still at an early stage, but I give you my word that for the Department of Defense, it will involve key opinion leaders in the headache field at those active military bases, prioritizing the bigger centers first, likely nearer to the East Coast, where our base is. Does that address what you asked, RK?

Swayampakula Ramakanth analyst
#24

Yes, yes. So, if I may, Mike, one more question for you; regarding Kaiser Permanente, this is one of those organizations where you truly need to develop internal KOLs who can fuel the product's growth. I'm not certain. Based on your experience, do you view that as a genuine approach? Or are there other levers that must be pulled? Because I think once you can get that moving, it can serve as a strong draw for the product.

Executive executive
#25

RK, that's an outstanding question. And I believe many companies ask the same thing regarding Kaiser since everyone recognizes how important a place like that is for business. I can't share every detail of our proposals so far with Kaiser. I have participated in many calls. I'm very enthusiastic about what we have happening with key opinion leader support inside Kaiser. It is an exceptionally well-organized and standardized group. So within the foundation, I know there's considerable support. So the work is certainly being done in the California market, and we're going to tackle some other opportunities outside of market. But I don't want to go too far into the Kaiser description of what will happen, but we now hold a very favorable position and we really just need to understand what's holding us back so we can create that necessity among the customers. But you are correct, we need internal providers requesting it. And I can tell you from my early meetings, we already have national headache and migraine experts doing that. So we're in a good spot. We've got to, I would say, tie a bow a little bit and determine what's missing, but we're gaining a lot of momentum there.

Swayampakula Ramakanth analyst
#26

Regarding Quell Fibromyalgia, you've got $2.5 million cumulative in the VA market. Within the VA, how large is the opportunity for Quell? And is there any chance outside the VA, since it seems it wasn't sold much as an over-the-counter type of product, given you now have considerable experience with Truvaga? I'm just trying to figure out how that could translate to Quell OTC, if that's what I can call it?

Executive executive
#27

That's a wonderful question, alright, since inside the VA, clearly, we're treating some multidisciplinary kinds of patients with multifactorial disorders; and fibromyalgia as a percentage represents a sizable population in the VA. I believe there are some recent statistics even just on active military. It's very low prior to deployment. But after coming back from deployment, it's roughly 11% just among active duty. So veterans overall are always facing greater and bigger issues. So it's a market in itself, which is very, very scalable for a product like Quell. Beyond the VA, I think all of us have family members and friends who've been coping with fibromyalgia; it's a big opportunity out there. But I'd say we mentioned Kaiser a bit earlier. I think those are the markets that would be the first ones to tackle as we keep exploring, perhaps some opportunities to speak with Triwest and Optum for some of the active military. That's the plan for at least the near term, but we still need to verify what the best spot is.

Josh Lev executive
#28

Also, RK, one thing really deserves mention when you consider how many sites are writing scripts for our medicines: for the fibromyalgia drug, prescriptions are coming from about one-third as many locations as those writing for gammaCore-S. So when you weigh that against the total opportunity ahead, remember we bought the company 12 months back. We managed to build that up to roughly $2.5 million inside the VA system. Yet within that VA system, it sits in just one part of the region. What we simply need is to invest more hours on the ground making sales. So I believe there's plenty of upside.

Swayampakula Ramakanth analyst
#29

I don't want to dominate the call, but I have one final question regarding Truvaga. What lessons are transferable from the U.S. to the U.K. side of things?

Josh Lev executive
#30

Excellent question. At this point, the only market where we've rolled out anything is the U.K., where we have our Truvaga 350. A great deal of inbound curiosity has come our way from the U.K., with individuals voicing a need or wish for greater access to vagus nerve, noninvasive vagal nerve stimulation within the wellness space. So things are at an early stage over there; January was when we actually introduced it; this is a soft launch. By that, I mean we aren't currently placing any media dollars behind it in an active way. What we're really aiming to do is gain a clearer picture of what the uptake looks like for that Truvaga 350 unit? And whether it's sensible, and what the broader business opportunity is, not merely in the U.K., but in additional regions beyond the U.S., and beyond the U.K. as well, for moving forward and launching a next-generation product such as the Truvaga?

Executive executive
#31

Appreciate that, Jeremy. Given the whole 4 weeks I've been at this, the easiest win sitting right in front of us is, like we talked about, the federal space. For me, the VA and what our veterans still aren't getting are a main priority; we recognize there's a genuinely big chance for us in that area and in other federal channels, as we discussed, with the Department of Defense. I'd say long-term plans make for a decent place to begin, yet everyone understands it's a fine spot to serve our veterans, though we can't stop there. That's why I believe the longer-term plan is going to keep pushing on the commercial segments and get that system sorted out, so it becomes our route to grow past the FSS and DSA opportunity. So that piece remains under development, remains being scoped out, but that's the long-term plan, letting us build revenue for the long term.

Josh Lev executive
#32

Absolutely, and that's a really good question. So, Jeremy, the first thing to note is that a modest group of Quell OTC users came to us through the NeuroMetrix acquisition. As you might remember, at NeuroMetrix's high point, its Quell over-the-counter business was generating roughly $12 million to $15 million. Much of that disappeared once the company made a strategic pivot, ran into the FTC issue, and shifted toward a medical device Quell fibromyalgia offering. From where we sit, our priority is, first, ensuring we can continue serving those legacy customers who've been using the product or who might wish to keep using it, even though it's no longer on the market — that's priority one. Priority two is doing this in a manner that guarantees we've resolved every concern NeuroMetrix had resolved with respect to the FTC. As for the broader rollout and commercial approach, the answer is that it will be gradual, clearly mapped out, yet intentional — we're deliberately making certain we've handled the issues NeuroMetrix encountered during their earlier go-round as an over-the-counter product, so we can proceed in a way that balances offering a Quell fibromyalgia FDA-cleared or FDA-approved product alongside a consumer product too.

Josh Lev executive
#33

Okay, Jeremy, once more — excellent question. I attempted to place real emphasis on this point as my remarks were wrapping up, yet the way we approach it is by considering 3 primary groups of catalysts. R&D comes first, meaning it might involve extra indications. PTSD is releasing further details regarding how the studies are progressing. Should you visit and keep up with our IR page, you'll see that we've issued recent press releases covering the ACACIA study along with certain other publications, where data is emerging that helps bolster what might become the foundation for a PTSD label. That would count as an R&D effort. Regarding products or features we brought up in connection with Truvaga and Quell, we're putting money into our second-generation, or next-generation, mobile application. Those features should let us reach a point where, assuming everything is executed properly, we'll find ourselves able to operate a recurring revenue model. So that's catalyst number one. Catalyst number two is commercial — being in a position to announce things like taking Truvaga beyond the United States, which we just did in January, plus the chance, or likelihood, of eventually bringing the Quell Relief or the Quell over-the-counter product to market as a stand-alone consumer product of its own. With luck, Mike steps up and we can announce either more momentum in places such as Kaiser, additional orders in the federal marketplace — federal workers' comp, maybe TRICARE — thereby unlocking various commercial pathways. Finally, the third catalyst is ultimately the operating results. Our belief is that we can reach a state where those other catalysts drive a larger total addressable market and greater uptake of noninvasive nerve stimulation products or devices. And we think that acceleration will produce stronger revenue growth, achieved while keeping our costs and expenses under control. So in the end, can we speed up revenue growth while simultaneously lowering our overall cost of doing so — whether measured by sales and marketing as a percentage of revenue or other such indicators, and so forth? Those are truly the 3 main catalysts receiving our attention, and we'll stay highly mindful of them as we move through the rest of 2026 and past that, so we can provide quite specific milestone updates on these various areas of strategic focus. Mike, I'm not sure whether there's anything more you'd like to add.

Executive executive
#34

Jeremy, let me also mention something from my opening remarks. Before arriving here, I already had some awareness of this company — specifically how deep the clinical focus runs at this site, and the ongoing work to keep strengthening that clinical platform. Since I came on board, having the chance to observe Dr. Stats alongside his team, plus all the investigator-initiated research and the funding this company directs toward the products so we can demonstrate more and accomplish more — that stands as one of the key reasons I feel tremendous enthusiasm about what lies ahead. So regarding acceleration, it isn't simply a matter of repeatedly deploying an identical product in an identical way while chasing momentum; rather, it means constructing the platform Josh described. To me, that represents a genuinely thrilling dimension of this organization: what lies ahead that we cannot talk about right now, yet the financial commitment and the work are being invested right here at electroCore to bring it about.

Josh Lev executive
#35

Amanda, thanks. I'd like to use this moment to express gratitude to those who hold shares in our company for sticking with us and for the encouragement you keep giving. To the people we treat, the clinicians who serve them, and the organizations we work alongside — we appreciate the confidence you place in us with your well-being and your schedules. And above all, to the members of our own team: thank you for arriving each day bringing the focus and the drive that this chance requires. I'm truly grateful that each of you joined us on this call. We can't wait to connect with all of you once more in the coming quarter, and I hope everyone enjoys a pleasant rest of the day.

Operator operator
#36

That concludes today's call. Thank you for your participation.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete electroCore, Inc. transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.

Get an API key View API docs →

For developers and AI pipelines

Programmatic access to electroCore, Inc. earnings transcripts and 132,000+ others is available through the EarningsAPI REST API and the hosted MCP server. Quarterly plans from $162 - full transcripts, speaker segments, full-text search, and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.